Overview

* VistaGen fiscal Q1 2026 net loss widens to $15.1 mln from $10.7 mln

* R&D expenses rose to $11.7 mln, driven by PALISADE Program for fasedienol

* Topline results for PALISADE-3 expected in Q4 2025, PALISADE-4 in H1 2026

Outlook

* Vistagen expects PALISADE-3 Phase 3 results in Q4 2025

* Topline results for PALISADE-4 expected in H1 2026

* Company preparing Phase 2 development for PH80 in menopausal hot flashes

* Vistagen planning further Phase 2 development for itruvone in MDD

Result Drivers

* R&D EXPENSES - Increase driven by PALISADE Program for fasedienol in social anxiety disorder

* PIPELINE ADVANCEMENT - Continued development of intranasal pherine product candidates across psychiatry, women's health, and cancer supportive care

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 EPS -$0.47

Q1 Net -$15.10

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Vistagen Therapeutics Inc ( VTGN ) is $12.00, about 75.3% above its August 6 closing price of $2.97

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)